While IFN-γ production may directly inhibit tumor growth in synergy with TNF-α (64, 65), it remains to be investigated whether CD103+CD4+ TILs are equally equipped to kill cancer cells as their CD103+CD8+ counterparts (19). The gene discussed is CD8A; the disease is neoplasm.